Differentiated Activity Profile for the PD-1 Inhibitor balstilimab. C.Joyce, et al.
RaPiDS (GOG-3028): A Randomized Phase II Study of balstilimab (AGEN2034) as Monotherapy or in Combination with zalifrelimab (AGEN1884) in Second-Line Cervical Cancer. O'Malley, et al.
The Dolaflexin-based antibody-drug conjugate XMT-1536 targets the solid tumor lineage antigen SLC34A2/NaPi2b. Bodyak, et al.
Pseudoprogression (PSP) Patterns: Analysis from 2 Independent Phase-2 Studies with Immunotherapy for Recurrent Cervical Cancer. O'Malley, et al.
Single-agent zalifrelimab (anti-CTLA-4) Shows Clinical Benefit in Rare Tumors – Case Reports from a Phase 2 Study (NCT02694822). Perez, et al.